ARECOR RECEIVES £2.8 MILLION GRANT AWARD FROM INNOVATE UK

Link to Full Article Coveted award for Phase II clinical development of lead product, AT247, its next generation ultra-rapid acting Insulin Cambridge, UK., 31 st Mar 2021: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has been awarded a £2.8 million grant from […]

ARECOR’S PARTNER INHIBRX EXERCISES ITS OPTION TO LICENSE A NEW FORMULATION DEVELOPED BY ARECOR IN ACCORDANCE WITH THE TERMS OF FORMULATION DEVELOPMENT AGREEMENT

Link to Full Article ARESTAT™ formulated product progressing into clinical trial Cambridge, UK., 17th December 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, […]

ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT247 IN DIABETES CARE

Link to Full Article AT247, a promising candidate in the pursuit for next generation insulins to improve glycemic control Cambridge, UK, 16 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of […]

ARECOR FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF ULTRA-CONCENTRATED RAPID ACTING INSULIN CANDIDATE, AT278, FOR DIABETES

Link to Full Article Development of a rapid acting concentrated insulin for advanced delivery systems and enabling fewer injections for high dose diabetics Cambridge, UK., 14 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives announces dosing of the first patient in a Phase I clinical […]

HIKMA AND ARECOR EXPAND COLLABORATION WITH NEW AGREEMENT TO DEVELOP AND COMMERCIALISE READY-TO-ADMINISTER MEDICINE

Link to Full Article Adds ready-to-administer injectable product to companies’ existing partnership London and Cambridge, October 20, 2020 – Hikma Pharmaceuticals PLC (Hikma or the Group), the multinational pharmaceutical company, and Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announce they have entered into a new exclusive agreement to co-develop […]

ARECOR PRESENTS POSITIVE RESULTS FOR THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA-RAPID ACTING INSULIN

Link to Full Article AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®   Cambridge, UK., 15 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, presented positive results for the Phase I clinical trial of its ultra-rapid acting […]

ARECOR ANNOUNCES ORAL PRESENTATION OF THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA RAPID ACTING INSULIN, AT THE AMERICAN DIABETES ASSOCIATION 80TH SCIENTIFIC SESSIONS

Cambridge, UK., 10 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I Study Investigating the PD, PK and Safety of AT247 in comparison with NovoRapid® and Fiasp®’, has been selected for oral presentation at the upcoming American Diabetes […]

ARECOR EXTENDS MULTI-PRODUCT COLLABORATION WITH CLINICAL STAGE BIOTECH

Link to Full Article Arecor innovative product formulations applied to oncology and rare orphan diseases Cambridge, UK, 19 March 2020: Arecor Limited (“Arecor” or “the Company”), the  biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has extended its multi-product collaboration with a US-based clinical stage biotechnology company. Under the collaboration, Arecor […]

ARECOR ACHIEVES SECOND LICENSE MILESTONE PAYMENT FROM GLOBAL PHARMACEUTICAL PARTNER

Link to Full Article Arecor formulated biosimilar product progressing through clinical studies Cambridge, UK., 25 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners. The first milestone was triggered […]

ARECOR SIGNS A NEW FEASIBILITY STUDY AGREEMENT WITH TOP FIVE PHARMA COMPANY

Link to Full Article Pharma partner has an exclusive option to a global, royalty bearing licence Cambridge, UK., 13 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with a top five pharmaceutical company. The pharmaceutical […]